Shots: The approval is based on pivotal P-II DESTINY-Breast01 study involves assessing of Enhertu (5.4 mg/kg) in 184 patients as a monothx. for patients with unresectable/m-HER2+ BC prior treated with […]readmore
Tags : HER2 Positive Metastatic Breast Cancer
Shots: The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally The P-II DESTINY- Breast01 […]readmore